0001209191-23-037320.txt : 20230615
0001209191-23-037320.hdr.sgml : 20230615
20230615161614
ACCESSION NUMBER: 0001209191-23-037320
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230613
FILED AS OF DATE: 20230615
DATE AS OF CHANGE: 20230615
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Mathers Edward T
CENTRAL INDEX KEY: 0001328625
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39397
FILM NUMBER: 231017546
MAIL ADDRESS:
STREET 1: C/O MEDIMMUNE, INC.
STREET 2: ONE MEDIMMUNE WAY
CITY: GAITHERSBURG
STATE: MD
ZIP: 20878
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Inozyme Pharma, Inc.
CENTRAL INDEX KEY: 0001693011
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 475129768
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 321 SUMMER STREET
STREET 2: SUITE 400
CITY: BOSTON
STATE: MA
ZIP: 02210
BUSINESS PHONE: 857-330-4340
MAIL ADDRESS:
STREET 1: 321 SUMMER STREET
STREET 2: SUITE 400
CITY: BOSTON
STATE: MA
ZIP: 02210
FORMER COMPANY:
FORMER CONFORMED NAME: Inozyme Pharma, LLC
DATE OF NAME CHANGE: 20161222
4
1
doc4.xml
FORM 4 SUBMISSION
X0407
4
2023-06-13
0
0001693011
Inozyme Pharma, Inc.
INZY
0001328625
Mathers Edward T
1954 GREENSPRING DRIVE
SUITE 600
TIMONIUM
MD
21093
1
0
0
0
0
Stock Option (right to buy)
6.18
2023-06-13
4
A
0
16000
0.00
A
2033-06-12
Common Stock
16000
16000
D
The option was granted on June 13, 2023. The shares underlying the option are scheduled to vest as to 100% of the shares on June 13, 2024, or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date.
/s/ Louis Citron, attorney-in-fact
2023-06-15